Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Bayer Gets Eylea Biosame Approval in Japan as It Braces for Biosimilar Debuts
February 22, 2022
-
BUSINESS Sleep Inducer Recalls by Fuji Yakuhin, Tatsumi Kagaku Tied to Tokyo Wholesaler’s Fake API Case
February 21, 2022
-
REGULATORY Japan Weighs Pre-Approval Purchase of Shionogi’s COVID-19 Pill
February 21, 2022
-
BUSINESS Chugai Claims 1st-Ever Title in Japan Pharma Market in 2021 on Brisk Oncologic Performance: IQVIA
February 18, 2022
-
BUSINESS Sawai to Launch Teribone Generic as Court Invalidates Patents; Asahi Kasei to Challenge Ruling
February 17, 2022
-
REGULATORY Japan Approves Slew of Generics towards June Listing; Samsca, Xarelto AGs Too
February 16, 2022
-
BUSINESS Pharma Officials Air Hopes and Concerns as Japan Moves to Enhance Supply Chain for Economic Security
February 15, 2022
-
REGULATORY Japan Snags 10 Million Extra Doses of Pfizer Vaccine
February 15, 2022
-
BUSINESS Chugai Joins Top Ranks in Japan Sales on Ronapreve Boon, Roche Collaboration
February 14, 2022
-
REGULATORY Pfizer’s Paxlovid Contraindicated with Many Medicines, Requires Careful Use
February 14, 2022
-
REGULATORY Japan Approves Pfizer’s Paxlovid, Second Oral COVID-19 Pill
February 10, 2022
-
ORGANIZATION Govt-Industry Arrangement for Drug Supply Survey Hits Rough Waters; FPMAJ Stands Pat on Continued Dialogue
February 10, 2022
-
REGULATORY Chuikyo Issues 2022 Reform Recommendation; Patch Prescription Limit Lowered to 63 Sheets
February 10, 2022
-
BUSINESS Chugai Sees Huge Potential in Its RAS Inhibitor with 15% of All Cancers Targeted: Research Chief
February 9, 2022
-
BUSINESS Insmed Plots Growth in Japan Biz with Arikayce and More Drugs to Follow
February 8, 2022
-
BUSINESS Shionogi Looks to File COVID Pill in Japan as Early as Next Week
February 8, 2022
-
REGULATORY Japan Mulls Early Conditional Approval for Shionogi’s COVID Pill
February 8, 2022
-
BUSINESS Pharma Industry Frets Cost and Deadline of MHLW-Ordered Carcinogen Risk Inspections
February 7, 2022
-
REGULATORY Lilly’s Retevmo Clears PAFSC for Thyroid Cancer; Lenvima/Keytruda to Get RCC Indication
February 7, 2022
-
BUSINESS Novartis Japan Developing Iptacopan as Priority Product, Initially Targeting 3 Indications
February 4, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…